Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00279734 · ClinicalTrials.gov registry record · Phase 1
Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers
A Phase 1 study of Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 80
- Enrollment target
- 3
- Study locations
NCT00279734 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 80 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT00279734, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 80 participants
- Enrollment target
- 3
- Study locations
Study Summary
Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.
Conditions Studied
Interventions
- DRUG Tetanus + pnemococcal vaccines alone
- DRUG Abatacept + vaccines
- DRUG Abatacept + Vaccines
Study Locations (3)
Kansas
- Qutintiles Phase I Services - Lenexa
Maryland
- Parexel International Corp - Baltimore
Texas
- PPD Development - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00279734
The ClinicalTrials.gov registry entry for NCT00279734 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 3 interventions - of which Tetanus + pnemococcal vaccines alone is the first listed.
NCT00279734 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Kansas, Maryland, Texas.
Frequently Asked Questions
What is clinical trial NCT00279734 about?
NCT00279734 is a clinical study titled "Vaccination Study of Abatacept (BMS-188667) for Normal Healthy Volunteers". Study to assess the ability of healthy subjects to build anitbodies to tetanus and pneumococcal vaccines after receiving a single intravenous dose of Abatacept, a drug which is being developed for the treatment of Rheumatoid Arthritis and which can affect the immune system.
What is the current status of trial NCT00279734?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2004-08. Estimated completion is 2005-01.
What conditions does trial NCT00279734 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT00279734?
The interventions under investigation include: Tetanus + pnemococcal vaccines alone (DRUG), Abatacept + vaccines (DRUG), Abatacept + Vaccines (DRUG).
Who is sponsoring clinical trial NCT00279734?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00279734 being conducted?
This trial has 3 study locations across Kansas, Maryland, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Study of GS-0151 in Participants With Rheumatoid Arthritis
RECRUITING · Phase 1
-
MAD Study of IA-14069
RECRUITING · Phase 1
-
A Study of AZD0120 in Autoimmune Diseases
RECRUITING · Phase 1
-
Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants
RECRUITING · Phase 1
-
Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.